| Gary R Albertson, DO | |
|
4303 Victory Dr, Austin, TX 78704-7507 | |
| (512) 462-3627 | |
| (512) 462-3431 |
| Full Name | Gary R Albertson |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 54 Years |
| Location | 4303 Victory Dr, Austin, Texas |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225063951 | NPI | - | NPPES |
| 128530606 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | D7899 (Texas) | Primary |
| 207Q00000X | Family Medicine | D7899 (Texas) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Privia Medical Group Gulf Coast Pllc | 4688999022 | 397 |
News Archive
Arrowhead Research Corporation, a targeted therapeutics company, today announced that the first patient has been dosed in a Phase 1 clinical trial with Adipotide, a new class of treatment for obesity.
Researchers at Harvard University Medical School have found as a result of a national survey that binge eating is far more common than anorexia and bulimia.
Antibiotic resistant E. coli was much more prevalent in villages situated along roads than in rural villages located away from roads, which suggests that roads play a major role in the spread or containment of antibiotic resistant bacteria, commonly called superbugs, a new study finds.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.
› Verified 8 days ago
| Entity Name | Privia Medical Group Gulf Coast Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578969465 PECOS PAC ID: 4688999022 Enrollment ID: O20150206000763 |
News Archive
Arrowhead Research Corporation, a targeted therapeutics company, today announced that the first patient has been dosed in a Phase 1 clinical trial with Adipotide, a new class of treatment for obesity.
Researchers at Harvard University Medical School have found as a result of a national survey that binge eating is far more common than anorexia and bulimia.
Antibiotic resistant E. coli was much more prevalent in villages situated along roads than in rural villages located away from roads, which suggests that roads play a major role in the spread or containment of antibiotic resistant bacteria, commonly called superbugs, a new study finds.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gary R Albertson, DO 4303 Victory Dr, Austin, TX 78704-7507 Ph: (512) 462-3627 | Gary R Albertson, DO 4303 Victory Dr, Austin, TX 78704-7507 Ph: (512) 462-3627 |
News Archive
Arrowhead Research Corporation, a targeted therapeutics company, today announced that the first patient has been dosed in a Phase 1 clinical trial with Adipotide, a new class of treatment for obesity.
Researchers at Harvard University Medical School have found as a result of a national survey that binge eating is far more common than anorexia and bulimia.
Antibiotic resistant E. coli was much more prevalent in villages situated along roads than in rural villages located away from roads, which suggests that roads play a major role in the spread or containment of antibiotic resistant bacteria, commonly called superbugs, a new study finds.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.
› Verified 8 days ago
Dr. Theophilus Shickel Painter Jr., MD Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 800 W 34th St, Ste 201, Austin, TX 78705 Phone: 512-454-5821 Fax: 512-459-9137 | |
Amin G Mery, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 4 Lakeway Centre Ct, Austin, TX 78734 Phone: 512-610-3110 Fax: 855-657-6065 | |
Dr. Edward John Peters, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 720 W 34th St Ste 200, Austin, TX 78705 Phone: 512-454-5821 Fax: 512-459-9137 | |
Howard Max Rosenblatt, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 1301 Barbara Jordan Blvd, #200, Austin, TX 78723 Phone: 512-628-1870 Fax: 512-628-1871 | |
Dr. Douglas Grey Barstow Jr., M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 3410 Far West Blvd, #146, Austin, TX 78731 Phone: 512-349-0777 Fax: 512-349-9111 | |
Dr. Maritza Navarro, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 11714 Wilson Parke Ave, Suite 150, Austin, TX 78726 Phone: 737-247-7200 Fax: 512-406-7368 |